Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7.

Grattan V, Vaino AR, Prensky Z, Hixon MS.

ACS Omega. 2019 Aug 15;4(9):14151-14154. doi: 10.1021/acsomega.9b02144. eCollection 2019 Aug 27.

2.

MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma.

Berggren KL, Restrepo Cruz S, Hixon MD, Cowan AT, Keysar SB, Craig S, James J, Barry M, Ozbun MA, Jimeno A, McCance DJ, Beswick EJ, Gan GN.

Oncogene. 2019 Nov;38(48):7329-7341. doi: 10.1038/s41388-019-0945-9. Epub 2019 Aug 15.

3.

Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.

Smith LC, Bremer PT, Hwang CS, Zhou B, Ellis B, Hixon MS, Janda KD.

J Am Chem Soc. 2019 Jul 3;141(26):10489-10503. doi: 10.1021/jacs.9b04872. Epub 2019 Jun 25.

4.

Noninvasive Urine Biomarker Lateral Flow Immunoassay for Monitoring Active Onchocerciasis.

Shirey RJ, Globisch D, Eubanks LM, Hixon MS, Janda KD.

ACS Infect Dis. 2018 Oct 12;4(10):1423-1431. doi: 10.1021/acsinfecdis.8b00163. Epub 2018 Sep 21.

5.

Synthetic molecules for disruption of the MYC protein-protein interface.

Jacob NT, Miranda PO, Shirey RJ, Gautam R, Zhou B, de Orbe Izquierdo ME, Hixon MS, Hart JR, Ueno L, Vogt PK, Janda KD.

Bioorg Med Chem. 2018 Aug 7;26(14):4234-4239. doi: 10.1016/j.bmc.2018.07.019. Epub 2018 Jul 11.

6.

Review of animal studies on the cardiovascular effects of caffeine.

Beyer LA, Hixon ML.

Food Chem Toxicol. 2018 Aug;118:566-571. doi: 10.1016/j.fct.2018.06.002. Epub 2018 Jun 2. Review.

PMID:
29864478
7.

Integrating larval connectivity with local demography reveals regional dynamics of a marine metapopulation.

Johnson DW, Christie MR, Pusack TJ, Stallings CD, Hixon MA.

Ecology. 2018 Jun;99(6):1419-1429. doi: 10.1002/ecy.2343.

PMID:
29856493
8.

Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes.

Lanier M, Cole DC, Istratiy Y, Klein MG, Schwartz PA, Tjhen R, Jennings A, Hixon MS.

J Med Chem. 2017 Jun 22;60(12):5209-5215. doi: 10.1021/acs.jmedchem.6b01224. Epub 2017 Jun 9.

9.

Derivation of an oral Maximum Allowable Dose Level for Bisphenol A.

Goodman JE, Peterson MK, Hixon ML, Pacheco Shubin S.

Regul Toxicol Pharmacol. 2017 Jun;86:312-318. doi: 10.1016/j.yrtph.2017.03.024. Epub 2017 Apr 1. Review.

10.

Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.

Sabat M, Wang H, Scorah N, Lawson JD, Atienza J, Kamran R, Hixon MS, Dougan DR.

Bioorg Med Chem Lett. 2017 May 1;27(9):1955-1961. doi: 10.1016/j.bmcl.2017.03.026. Epub 2017 Mar 14.

PMID:
28359790
11.

MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody.

Farrell PJ, Matuszkiewicz J, Balakrishna D, Pandya S, Hixon MS, Kamran R, Chu S, Lawson JD, Okada K, Hori A, Mizutani A, Iwata H, de Jong R, Hibner B, Vincent P.

Mol Cancer Ther. 2017 Jul;16(7):1269-1278. doi: 10.1158/1535-7163.MCT-16-0771. Epub 2017 Mar 24.

12.

T-3364366 Targets the Desaturase Domain of Delta-5 Desaturase with Nanomolar Potency and a Multihour Residence Time.

Miyahisa I, Suzuki H, Mizukami A, Tanaka Y, Ono M, Hixon MS, Matsui J.

ACS Med Chem Lett. 2016 Aug 10;7(9):868-72. doi: 10.1021/acsmedchemlett.6b00241. eCollection 2016 Sep 8.

13.

Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors.

Wang H, Lawson JD, Scorah N, Kamran R, Hixon MS, Atienza J, Dougan DR, Sabat M.

Bioorg Med Chem Lett. 2016 Sep 1;26(17):4334-9. doi: 10.1016/j.bmcl.2016.07.030. Epub 2016 Jul 16.

PMID:
27460209
14.

Fragment-based drug discovery of potent and selective MKK3/6 inhibitors.

Adams M, Kobayashi T, Lawson JD, Saitoh M, Shimokawa K, Bigi SV, Hixon MS, Smith CR, Tatamiya T, Goto M, Russo J, Grimshaw CE, Swann S.

Bioorg Med Chem Lett. 2016 Feb 1;26(3):1086-1089. doi: 10.1016/j.bmcl.2015.11.054. Epub 2015 Nov 17.

PMID:
26704264
15.

Rapid Determination of the Specificity Constant of Irreversible Inhibitors (kinact/KI) by Means of an Endpoint Competition Assay.

Miyahisa I, Sameshima T, Hixon MS.

Angew Chem Int Ed Engl. 2015 Nov 16;54(47):14099-102. doi: 10.1002/anie.201505800. Epub 2015 Oct 1.

PMID:
26426864
16.

Using post-settlement demography to estimate larval survivorship: a coral reef fish example.

Johnson DW, Christie MR, Stallings CD, Pusack TJ, Hixon MA.

Oecologia. 2015 Nov;179(3):729-39. doi: 10.1007/s00442-015-3368-5. Epub 2015 Jun 21.

PMID:
26093629
17.

Toward the discovery of dual inhibitors for botulinum neurotoxin A: concomitant targeting of endocytosis and light chain protease activity.

Seki H, Xue S, Hixon MS, Pellett S, Remes M, Johnson EA, Janda KD.

Chem Commun (Camb). 2015 Apr 11;51(28):6226-9. doi: 10.1039/c5cc00677e.

PMID:
25759983
18.

A simple and widely applicable hit validation strategy for protein-protein interaction inhibitors based on a quantitative ligand displacement assay.

Sameshima T, Miyahisa I, Homma M, Aikawa K, Hixon MS, Matsui J.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5836-5839. doi: 10.1016/j.bmcl.2014.09.073. Epub 2014 Oct 2.

PMID:
25452002
19.

Parasitism in Pterois volitans (Scorpaenidae) from coastal waters of Puerto Rico, the Cayman Islands, and the Bahamas.

Ramos-Ascherl Z, Williams EH Jr, Bunkley-Williams L, Tuttle LJ, Sikkel PC, Hixon MA.

J Parasitol. 2015 Feb;101(1):50-6. doi: 10.1645/13-422.1. Epub 2014 Oct 10.

PMID:
25302790
20.

Probing BoNT/A protease exosites: implications for inhibitor design and light chain longevity.

Xue S, Javor S, Hixon MS, Janda KD.

Biochemistry. 2014 Nov 4;53(43):6820-4. doi: 10.1021/bi500950x. Epub 2014 Oct 21.

21.

A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity.

Harris TL, Lowery CA, Hixon MS, Janda KD.

ACS Chem Neurosci. 2014 Aug 20;5(8):632-6. doi: 10.1021/cn500135h. Epub 2014 Jul 11.

22.

Benzoquinones as inhibitors of botulinum neurotoxin serotype A.

Bremer PT, Hixon MS, Janda KD.

Bioorg Med Chem. 2014 Aug 1;22(15):3971-81. doi: 10.1016/j.bmc.2014.06.004. Epub 2014 Jun 16.

23.

Spatial and temporal patterns of larval dispersal in a coral-reef fish metapopulation: evidence of variable reproductive success.

Pusack TJ, Christie MR, Johnson DW, Stallings CD, Hixon MA.

Mol Ecol. 2014 Jul;23(14):3396-408. doi: 10.1111/mec.12824. Epub 2014 Jul 1.

PMID:
24917250
24.

ATP allosterically activates the human 5-lipoxygenase molecular mechanism of arachidonic acid and 5(S)-hydroperoxy-6(E),8(Z),11(Z),14(Z)-eicosatetraenoic acid.

Smyrniotis CJ, Barbour SR, Xia Z, Hixon MS, Holman TR.

Biochemistry. 2014 Jul 15;53(27):4407-19. doi: 10.1021/bi401621d. Epub 2014 Jul 2.

25.

A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT).

Lanier M, Ambrus G, Cole DC, Davenport R, Ellery J, Fosbeary R, Jennings AJ, Kadotani A, Kamada Y, Kamran R, Matsumoto S, Mizukami A, Okubo S, Okada K, Saikatendu K, Walsh L, Wu H, Hixon MS.

J Med Chem. 2014 Jun 26;57(12):5459-63. doi: 10.1021/jm500475k. Epub 2014 Jun 4.

PMID:
24847974
26.

Low susceptibility of invasive red lionfish (Pterois volitans) to a generalist ectoparasite in both its introduced and native ranges.

Sikkel PC, Tuttle LJ, Cure K, Coile AM, Hixon MA.

PLoS One. 2014 May 5;9(5):e95854. doi: 10.1371/journal.pone.0095854. eCollection 2014.

27.

Anatomical location and redistribution of G protein-coupled estrogen receptor-1 during the estrus cycle in mouse kidney and specific binding to estrogens but not aldosterone.

Cheng SB, Dong J, Pang Y, LaRocca J, Hixon M, Thomas P, Filardo EJ.

Mol Cell Endocrinol. 2014 Feb 15;382(2):950-9. doi: 10.1016/j.mce.2013.11.005. Epub 2013 Nov 13.

PMID:
24239983
28.

Probing the effects of hapten stability on cocaine vaccine immunogenicity.

Cai X, Whitfield T, Moreno AY, Grant Y, Hixon MS, Koob GF, Janda KD.

Mol Pharm. 2013 Nov 4;10(11):4176-84. doi: 10.1021/mp400214w. Epub 2013 Oct 4.

29.

Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors.

Gangloff AR, Brown J, de Jong R, Dougan DR, Grimshaw CE, Hixon M, Jennings A, Kamran R, Kiryanov A, O'Connell S, Taylor E, Vu P.

Bioorg Med Chem Lett. 2013 Aug 15;23(16):4501-5. doi: 10.1016/j.bmcl.2013.06.055. Epub 2013 Jun 24.

PMID:
23850199
30.

Mechanistic insights into the LsrK kinase required for autoinducer-2 quorum sensing activation.

Zhu J, Hixon MS, Globisch D, Kaufmann GF, Janda KD.

J Am Chem Soc. 2013 May 29;135(21):7827-30. doi: 10.1021/ja4024989. Epub 2013 May 16.

31.

Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design.

Cai X, Whitfield T, Hixon MS, Grant Y, Koob GF, Janda KD.

J Med Chem. 2013 May 9;56(9):3701-9. doi: 10.1021/jm400228w. Epub 2013 Apr 29.

32.

The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic Cleft.

Silhár P, Lardy MA, Hixon MS, Shoemaker CB, Barbieri JT, Struss AK, Lively JM, Javor S, Janda KD.

ACS Med Chem Lett. 2013 Feb 14;4(2):283-287. Epub 2012 Dec 23.

33.

Onchocerca volvulus-neurotransmitter tyramine is a biomarker for river blindness.

Globisch D, Moreno AY, Hixon MS, Nunes AA, Denery JR, Specht S, Hoerauf A, Janda KD.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4218-23. doi: 10.1073/pnas.1221969110. Epub 2013 Feb 25.

34.

A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases.

Iwata H, Oki H, Okada K, Takagi T, Tawada M, Miyazaki Y, Imamura S, Hori A, Lawson JD, Hixon MS, Kimura H, Miki H.

ACS Med Chem Lett. 2012 Feb 28;3(4):342-6. doi: 10.1021/ml3000403. eCollection 2012 Apr 12.

35.

Reproductive effects in F1 adult females exposed in utero to moderate to high doses of mono-2-ethylhexylphthalate (MEHP).

Moyer B, Hixon ML.

Reprod Toxicol. 2012 Aug;34(1):43-50. doi: 10.1016/j.reprotox.2012.02.006. Epub 2012 Mar 6.

36.

Incidence and nature of testicular toxicity findings in pharmaceutical development.

Sasaki JC, Chapin RE, Hall DG, Breslin W, Moffit J, Saldutti L, Enright B, Seger M, Jarvi K, Hixon M, Mitchard T, Kim JH.

Birth Defects Res B Dev Reprod Toxicol. 2011 Dec;92(6):511-25. doi: 10.1002/bdrb.20338. Review.

PMID:
22162370
37.

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.

Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A.

J Clin Oncol. 2011 Dec 1;29(34):4534-40. doi: 10.1200/JCO.2010.33.0670. Epub 2011 Oct 24.

38.

Functional responses and scaling in predator-prey interactions of marine fishes: contemporary issues and emerging concepts.

Hunsicker ME, Ciannelli L, Bailey KM, Buckel JA, Wilson White J, Link JS, Essington TE, Gaichas S, Anderson TW, Brodeur RD, Chan KS, Chen K, Englund G, Frank KT, Freitas V, Hixon MA, Hurst T, Johnson DW, Kitchell JF, Reese D, Rose GA, Sjodin H, Sydeman WJ, van der Veer HW, Vollset K, Zador S.

Ecol Lett. 2011 Dec;14(12):1288-99. doi: 10.1111/j.1461-0248.2011.01696.x. Epub 2011 Oct 11. Review.

PMID:
21985428
39.

Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization.

Zakhari JS, Kinoyama I, Hixon MS, Di Mola A, Globisch D, Janda KD.

Bioorg Med Chem. 2011 Nov 1;19(21):6203-9. doi: 10.1016/j.bmc.2011.09.019. Epub 2011 Sep 14.

40.

Identification of α2 macroglobulin as a major serum ghrelin esterase.

Eubanks LM, Stowe GN, De Lamo Marin S, Mayorov AV, Hixon MS, Janda KD.

Angew Chem Int Ed Engl. 2011 Nov 4;50(45):10699-702. doi: 10.1002/anie.201104512. Epub 2011 Sep 16. No abstract available.

41.

Effects of in utero exposure to Bisphenol A or diethylstilbestrol on the adult male reproductive system.

LaRocca J, Boyajian A, Brown C, Smith SD, Hixon M.

Birth Defects Res B Dev Reprod Toxicol. 2011 Dec;92(6):526-33. doi: 10.1002/bdrb.20336. Epub 2011 Sep 15.

42.

Akt1 is essential for postnatal mammary gland development, function, and the expression of Btn1a1.

LaRocca J, Pietruska J, Hixon M.

PLoS One. 2011;6(9):e24432. doi: 10.1371/journal.pone.0024432. Epub 2011 Sep 7.

43.

Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.

Iwata H, Imamura S, Hori A, Hixon MS, Kimura H, Miki H.

Bioorg Med Chem. 2011 Sep 15;19(18):5342-51. doi: 10.1016/j.bmc.2011.08.002. Epub 2011 Aug 6.

PMID:
21885287
44.

Genetic correlations between adults and larvae in a marine fish: potential effects of fishery selection on population replenishment.

Johnson DW, Christie MR, Moye J, Hixon MA.

Evol Appl. 2011 Sep;4(5):621-33. doi: 10.1111/j.1752-4571.2011.00185.x. Epub 2011 Apr 2.

45.

Developmental toxicity testing for safety assessment: new approaches and technologies.

Knudsen TB, Kavlock RJ, Daston GP, Stedman D, Hixon M, Kim JH.

Birth Defects Res B Dev Reprod Toxicol. 2011 Oct;92(5):413-20. doi: 10.1002/bdrb.20315. Epub 2011 Jul 18. Review.

PMID:
21770025
46.

Sexual and lifetime selection on body size in a marine fish: the importance of life-history trade-offs.

Johnson DW, Hixon MA.

J Evol Biol. 2011 Aug;24(8):1653-63. doi: 10.1111/j.1420-9101.2011.02298.x. Epub 2011 May 23.

47.

A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action.

Salzameda NT, Eubanks LM, Zakhari JS, Tsuchikama K, DeNunzio NJ, Allen KN, Hixon MS, Janda KD.

Chem Commun (Camb). 2011 Feb 14;47(6):1713-5. doi: 10.1039/c0cc04078a. Epub 2011 Jan 4.

48.

Larval connectivity in an effective network of marine protected areas.

Christie MR, Tissot BN, Albins MA, Beets JP, Jia Y, Ortiz DM, Thompson SE, Hixon MA.

PLoS One. 2010 Dec 21;5(12):e15715. doi: 10.1371/journal.pone.0015715.

49.

Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism.

Iwata H, Imamura S, Hori A, Hixon MS, Kimura H, Miki H.

Biochemistry. 2011 Feb 8;50(5):738-51. doi: 10.1021/bi101777f. Epub 2011 Jan 10.

PMID:
21182308
50.

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.

Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN.

Br J Cancer. 2011 Jan 4;104(1):68-74. doi: 10.1038/sj.bjc.6605972. Epub 2010 Nov 23. Retraction in: Br J Cancer. 2012 Dec 4;107(12):2024.

Supplemental Content

Support Center